Piet L C M van Riel
Overview
Explore the profile of Piet L C M van Riel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
195
Citations
7645
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spijk-de Jonge M, Manders S, Huis A, Elwyn G, van de Laar M, van Riel P, et al.
Mediterr J Rheumatol
. 2021 Aug;
32(1):21-30.
PMID: 34386699
Objective: The systematic development of an intervention to improve disease activity-based management of rheumatoid arthritis (RA) in daily clinical practice that is based on patient-level barriers. Methods: The self-management strategy...
2.
Muskens W, Rongen-van Dartel S, Vogel C, Huis A, Adang E, van Riel P
Rheumatol Adv Pract
. 2021 Mar;
5(1):rkaa079.
PMID: 33688619
Objectives: We aimed to evaluate the use of an eHealth platform and a self-management outpatient clinic in patients with RA in a real-world setting. The effects on health-care utilization and...
3.
Weijers J, Muskens W, van Riel P
RMD Open
. 2021 Jan;
7(1).
PMID: 33504577
Obesity is very common in patients with inflammatory rheumatic diseases (IRDs), of which between 27% and 37% of patients have a body mass index ≥30 kg/m In addition to further...
4.
Muskens W, Rongen-van Dartel S, van Riel P, Adang E
J Rheumatol
. 2020 Nov;
48(12):1803-1809.
PMID: 33132223
Objective: The market entry of biosimilars is expected to bring budgetary relief. Our objective was to determine how the introduction of biosimilars influences medication costs in patients with rheumatoid arthritis...
5.
Muskens W, Rongen-van Dartel S, Teerenstra S, Adang E, van Riel P
Rheumatol Adv Pract
. 2020 Oct;
4(2):rkaa042.
PMID: 33005860
Objective: The aim was to study the effect of non-mandatory transitioning from etanercept originator to etanercept biosimilar on retention rates in a setting promoting shared decision-making. Methods: In 2016, all...
6.
Spijk-de Jonge M, Oude Voshaar M, Renskers L, Huis A, van de Laar M, Hulscher M, et al.
Rheumatol Adv Pract
. 2020 Jul;
4(2):rkaa012.
PMID: 32704614
Objective: The aim was to develop two disease- and treatment-related knowledge about RA (DataK-RA) short forms using item response theory-based linear optimal test design. Methods: We used the open source...
7.
Muskens W, Rongen-van Dartel S, Adang E, van Riel P
Mediterr J Rheumatol
. 2020 Jun;
30(Suppl 1):76-81.
PMID: 32524082
These days, the use of biosimilars for the treatment of bio-naive patients is well established. However, the transition of patients being treated with a bio-originator to its biosimilar is still...
8.
Weijers J, Rongen-van Dartel S, van Riel P
Mediterr J Rheumatol
. 2020 Mar;
29(4):199-206.
PMID: 32185327
Objective: This study evaluates exercise participation in patients with rheumatoid arthritis (RA) and the percentage of patients that meet the recommended level of physical activity (at least 150 minutes per...
9.
Weijers J, Semb A, Rollefstad S, Kitas G, van Riel P
Rheumatol Int
. 2020 Feb;
40(4):523-527.
PMID: 32088752
The aim was to study the different strategies used to implement cardiovascular risk evaluation and management for patients with rheumatoid arthritis (RA) in daily clinical practice. A questionnaire survey was...
10.
Spijk-de Jonge M, Weijers J, Boerboom L, Huis A, Atsma F, Van Hulst L, et al.
Clin Rheumatol
. 2020 Jan;
39(4):1131-1139.
PMID: 31997083
To re-evaluate the adherence to clinical practice guidelines recommended disease activity-based management of rheumatoid arthritis (RA) in daily clinical practice, among Dutch rheumatologists in the past decade. In 2007, disease...